Baxter International Inc vs Clorox Co — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Clorox Co trades at $95 (market cap $11.46B). The key difference: Baxter International Inc and Clorox Co are close in size by market cap, and Clorox Co pays the higher dividend (5.23%). Which is the better fit depends on your goals.
| BAX | CLX | |
|---|---|---|
Market Cap | $11.26B | $11.46B |
Sector | Health | Consumer Staples |
52-Week High | $29.22 | $131.43 |
52-Week Low | $15.80 | $86.12 |
Enterprise Value | $18.93B | $14.76B |
Dividend Yield | 0.92% | 5.23% |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
CLX trades at $95.05, down 1.56% on the day, with technical indicators showing a bearish trend. The company reported strong Q1 2026 earnings beat with EPS of $1.64 versus $1.55 expected, though revenue trends remain flat. Recent corporate developments include a simplified operating structure announcement and CEO transition for health reasons. The stock offers a 5%+ dividend yield with recent H1-26 dividend of $1.24 payable May 2026.
CLX presents a mixed outlook with attractive dividend income but faces growth challenges. The 8.7% upside to consensus price target of $103.38 suggests moderate potential, though high P/B ratio of 41.4 and declining revenue projections for 2026 warrant caution. Key risks include execution of new operating structure and competitive pressures in consumer staples.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →